ABSTRACT
Objective While epilepsy research has largely focused on medical management and clinical outcomes, less attention has been given to the unmet psychosocial, and everyday needs of people with epilepsy (PWE), particularly in low- and middle-income countries. The Global Epilepsy Needs Study (GENS) aims to explore these needs, which are integral to quality of life, by capturing both shared and context-specific experiences.
Methods GENS employed a patient-centered approach and mixed-methods design, integrating a cross-sectional survey and semi-structured interviews in 15 countries. The survey, available in 12 languages, captured experiences across 10 life domains (n=5296). Interviews, analysed thematically using a phenomenological approach and Colaizzi’s Method, explored lived experiences in depth (n=75). To ensure meaningful involvement and diverse representation, national patient associations, healthcare professionals, researchers and people with lived experience guided each stage of the research process, from study design to manuscript development.
Results Quantitative and qualitative data were integrated using a joint display method. This analysis generated 5 Generalised Themes across all life domains: 1) Managing uncertainty and redefining daily life; 2) Living with risk, social exclusion, and misunderstanding; 3) Challenges in navigating inaccessible systems; 4) Consequences of inaccessible or inadequate information; and 5) Complex epilepsy needs demand more than standard approaches.
Significance This first-of-its-kind global study offers a comprehensive picture of the psychosocial and everyday challenges faced by PWE. It establishes a critical evidence base for epilepsy organisations, highlights the need for healthcare systems to adopt holistic, multidisciplinary approaches, and calls on policymakers to invest in systemic reforms that safeguard dignity, inclusion, and life opportunities. Future research should explore the needs of underserved groups, including caregivers, individuals with complex epilepsy, women, and those in low-income or rural settings.
Plain Language Summary This study looked at the everyday challenges faced by people with epilepsy in different parts of the world. It showed that many people struggle with fear, stigma, poor access to services, and a lack of clear information and support. Women, people in rural areas, and those in low-income settings often face the greatest challenges. The study calls for better education, more support for caregivers, and improvements across health, work, school, and transport systems. It also shows the need for more research to understand and respond to the real-life needs of people most impacted by epilepsy.
Competing Interest Statement
SKB, CH, PGP and AR received research consultancy fees from IBE. AK receives salary support for consulting activities on behalf of The International Bureau for Epilepsy, a non-profit organization. She also provides paid support to the American Epilepsy Society in support of PAME activities. She is a paid advisor for Neurelis Pharmaceuticals and UCB. She has also received travel support from the Epilepsy Foundation. LFP has served as advisory board and speaker for continuous education programs for the companies UCB, LIVANOVA, TORRENT, ABBOTT, LIBBS, ADIUM, BIOLAB, EUROFARMA and PRATI-DONADUZZI. JHC has acted as an investigator for studies with Jazz/GW Pharmaceuticals, Marinus, Stoke Therapeutics, UCB/Zogenix, Ultragenyx, Encoded and Vitaflo; has been a speaker and has served on advisory boards for Biocodex, Jazz Pharmaceuticals, Nutricia, Stoke Therapeutics, and UCB (all remuneration has been paid to her department); holds an endowed chair at the University College of London Great Ormond Street Institute of Child Health; has received grants from the National Institute for Health and Care Research (NIHR), the Engineering and Physical Sciences Research Council (EPSRC), the Great Ormond Street Hospital for Children (GOSH) Charity, LifeArc, and Epilepsy Research UK; and her research is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. She is President of the International League Against Epilepsy 2021-2025. GS has grants from the Indian Council of Medical Research and Wellcome Trust. He is President of the Indian Epilepsy Association and Chair of the Education Council, International League Against Epilepsy. The remaining authors have no conflict of interest.
Funding Statement
The following pharmaceutical companies have provided financial support to the development of Phase 1 of the Global Epilepsy Needs Study, documented in this manuscript, through grants to the International Bureau for Epilepsy: Angelini Pharma, Jazz Pharmaceuticals, Takeda Pharmaceuticals and UCB. These companies have had no editorial influence on this research article. Funds were used to contract the research consultancy (MediPace), cover project management fees (for IBE and its chapters), reimburse contributors, support translation and dissemination costs, and offset other miscellaneous expenses.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Argentina obtained formal approval from the Comite de Etica en Investigacion en Salud del Adulto (CEIS del Adulto). Australia PAG confirmed exemption as per advice from Chris Peterson, researcher linked to La Trobe University Ethics. Bosnia & Herzegovina obtained a formal exception from the Ethics Committee at University of East Sarajevo. Brazil obtained formal approval from Instituto Jo Clemente (IJC). Canada obtained a formal exemption from the Community Research Ethics Office. China obtained a formal approval from the Biomedical Ethics Review Committee of West China Hospital, Sichuan University. Hong Kong obtained approval by the Human Research Ethics Committee (HREC) from The University of Hong Kong. Croatia was granted approval from the Ethics Committee of the Croatian Association for Epilepsy, Chaired by Dr. Ana Sruk, MD [Note: PAG lead approved the study]. Denmark was exempted in accordance with section 14(2) of the Danish Act on Committees and the Danish Research Ethics Committees, following guidance from the Videnskabsetisk Medicinsk Komite (VMK) and the Nationale Videnskabsetiske Komite (NVK). The Gambia, obtained approval by the Ministry of Health through Dr. Momodou T. Nyassi. India obtained approval from Institutional Ethics Committee (IEC), Dayanand Medical College & Hospital. South Korea obtained approval from the Public Institutional Review Board for Life Sciences, Ministry of Health and Welfare (Seoul). Spain Chapter confirmed approval from the Ethics Committee from Fundacion Jimenez Diaz. Tunisia obtained approval from the Ethics Committee at Hedi Chaker University Hospital, Sfax, Tunisia. Uganda obtained approval from the Research Ethics Committee, School of Social Sciences, Makerere University. The United States obtained formal exemption from the WIRB-Copernicus Group Institutional Review Board (WCG IRB).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The original contributions generated for this study are included in the article and its Supporting Material (the Integration Framework developed for the GENS study). Further inquiries can be directed to the corresponding author.
